市場調查報告書
商品編碼
1084804

食道癌治療藥的市場規模、佔有率、展望、機會 (2022年∼2028年):各治療類型 (化療、標的藥物療法、免疫療法)、適應症、流通管道、地區

Esophageal Cancer Drugs Market, By Therapy Type (Chemotherapy, Targeted Drug Therapy, and Immunotherapy ), By Disease Indication, By Distribution Channel, and By Region - Size, Share, Outlook, and Opportunity Analysis, 2022 - 2028

出版日期: | 出版商: Coherent Market Insights | 英文 166 Pages | 商品交期: 2-3個工作天內

價格
  • 全貌
  • 簡介
  • 目錄
簡介

全球食道癌的盛行率增加促進食道癌治療藥市場成長。

本報告提供全球食道癌治療藥的市場調查,市場定義和概要,市場成長的各種影響因素分析,法律制度,技術趨勢,市場規模的變化、預測,各種區分、各地區/主要國家的明細,競爭環境,主要企業簡介等彙整資訊。

目錄

第1章 調查目的、前提條件

第2章 市場概要

第3章 市場動態、法律規章、趨勢分析

  • 市場動態
    • 促進因素
    • 阻礙因素
    • 市場機會
  • 影響分析
  • 市場趨勢
  • 主要的展開
  • 法規情形
  • 產品回收
  • 流行病學分析
  • 技術概要
  • PEST分析
  • 波特的五力分析

第4章 全球食道癌治療藥市場:各治療類型

  • 化療
  • 標的藥物療法
  • 免疫療法

第5章 全球食道癌治療藥市場:各適應症

  • 腺癌
  • 胃腸道基質腫瘤
  • 類癌
  • 鱗狀細胞癌
  • 其他

第6章 全球食道癌治療藥市場:各流通管道

  • 醫院藥局
  • 零售藥局
  • 線上藥局

第7章 全球食道癌治療藥市場:各地區

  • 北美
  • 歐洲
  • 亞太地區
  • 南美
  • 非洲
  • 中東

第8章 競爭情形

  • 企業簡介
    • Amgen Inc.
    • Eli Lilly and Company
    • F. Hoffmann-La Roche
    • Bristol-Myers Squibb Company
    • Boehringer Ingelheim GmbH
    • Bristol-Myers Squibb
    • GlaxoSmithKline Plc.
    • Novartis AG
    • Johnson &Johnson
    • Gilead Sciences
    • Genentech Inc.
    • Sanofi-Aventis
    • Merck &Co.
  • 分析師的見解

第9章 Section

目錄
Product Code: CMI3036

Esophageal cancer occurs in the cells that line the inside of the esophagus. Major symptoms include difficulty in swallowing (dysphagia), unintentional weight loss, chest pain, worsening indigestion or heartburn, coughing or hoarseness. Drugs approved by the Food and Drug Administration (FDA) such as Docetaxel, Trifluridine, and Tipiracil Hydrochloride are extensively used chemotherapy for treatment of esophageal cancer. Immunotherapy drug named Pembrolizumab is also used for the treatment of esophageal cancer. In 2017, FDA granted accelerated approval to pembrolizumab (Keytruda) for patients suffering from recurrent locally advanced or metastatic, gastric or gastroesophageal junction adenocarcinoma.

Market Dynamics

Increasing prevalence of esophageal cancer worldwide is expected to boost esophageal cancer drugs market growth. According to World Cancer Research Fund (WCRF) International 2021, esophageal cancer is the seventh most commonly occurring cancer in men and the 13th most commonly occurring cancer in women. There were over 500,000 new cases in 2021, globally. Moreover, geriatric population is at high risk of developing esophageal cancer and men are more vulnerable to developing esophageal cancer. For instance, according to a data published in American Society of Clinical Oncology (ASCO) in 2021, it is estimated that people between the ages of 45 and 70 have the highest risk of esophageal cancer.

However, no drug therapy has been used to cure esophageal cancer completely and the survival rates of esophageal cancer patient significantly decreases after 5 years of treatment. The esophageal cancer drugs do not have any reliability after 5 years of treatment, which is expected to hamper growth of the esophageal cancer drugs market. For instance, according to the study published in the ASCO in January 2019, the 5-year survival rate of people with esophageal cancer is 19%.

Key features of the study:

  • This report provides in-depth analysis of the esophageal cancer drugs market, market size (US$ Mn), and Compound Annual Growth Rate (CAGR (%)) for the forecast period (2022-2028), considering 2021 as the base year
  • It elucidates potential revenue opportunity across different segments and explains attractive investment proposition matrix for this market
  • This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by leading players
  • It profiles key players in the global esophageal cancer drugs market based on the following parameters - company overview, financial performance, product portfolio, geographical presence, distribution strategies, key developments, and strategies
  • Key players covered as a part of this study include Amgen Inc., Eli Lilly and Company, F. Hoffmann-La Roche, Bristol-Myers Squibb Company, Boehringer Ingelheim GmbH, Bristol-Myers Squibb, GlaxoSmithKline Plc., Novartis AG, Johnson & Johnson, Gilead Sciences, Genentech, Inc., Sanofi-Aventis, and Merck & Co.
  • Insights from this report would allow marketers and management authorities of companies to make informed decision with respect to their future product launch, governmental initiatives, technological up-gradation, market expansion, and marketing tactics
  • The global esophageal cancer drugs market report caters to various stakeholders in this industry, including investors, product manufacturers, distributors, suppliers, research and consulting firms, new entrants, and financial analysts

Detailed Segmentation:

  • Global Esophageal Cancer Drugs Market, By Therapy Type:
  • Chemotherapy
    • Docetaxel
    • Irinotecan
    • Trifluridine and Tipiracil
    • Carboplatin and Paclitaxel
    • Cisplatin and 5-fluorouracil
    • Cisplatin with Capecitabine
  • Targeted Drug Therapy
    • Trastuzumab
    • Ramucirumab
  • Immunotherapy
    • Pembrolizumab
  • Global Esophageal Cancer Drugs Market, By Disease Indication:
  • Adenocarcinomas
  • Gastrointestinal Stromal Tumors
  • Carcinoid Tumors
  • Squamous Cell Carcinoma
  • Others
  • Global Esophageal Cancer Drugs Market, By Distribution Channel:
  • Hospital Pharmacy
  • Retail Pharmacy
  • Online Pharmacy
  • Global Esophageal Cancer Drugs Market, By Region:
  • North America
    • By Country:
  • U.S.
  • Canada
    • By Therapy Type:
  • Chemotherapy
  • Docetaxel
  • Irinotecan
  • Trifluridine and Tipiracil
  • Carboplatin and Paclitaxel
  • Cisplatin and 5-fluorouracil
  • Cisplatin with Capecitabine
  • Targeted Drug Therapy
  • Trastuzumab
  • Ramucirumab
  • Immunotherapy
  • Pembrolizumab
    • By Disease Indication:
  • Adenocarcinomas
  • Gastrointestinal Stromal Tumors
  • Carcinoid Tumors
  • Squamous Cell Carcinoma
  • Others
    • By Distribution Channel:
  • Hospital Pharmacy
  • Retail Pharmacy
  • Online Pharmacy
  • Europe
    • By Country:
  • U.K.
  • Germany
  • Italy
  • Spain
  • France
  • Russia
  • Rest of Europe
    • By Therapy Type:
  • Chemotherapy
  • Docetaxel
  • Irinotecan
  • Trifluridine and Tipiracil
  • Carboplatin and Paclitaxel
  • Cisplatin and 5-fluorouracil
  • Cisplatin with Capecitabine
  • Targeted Drug Therapy
  • Trastuzumab
  • Ramucirumab
  • Immunotherapy
  • Pembrolizumab
    • By Disease Indication:
  • Adenocarcinomas
  • Gastrointestinal Stromal Tumors
  • Carcinoid Tumors
  • Squamous Cell Carcinoma
  • Others
    • By Distribution Channel:
  • Hospital Pharmacy
  • Retail Pharmacy
  • Online Pharmacy
  • Asia Pacific
    • By Country:
  • Australia
  • India
  • China
  • Japan
  • ASEAN
  • South Korea
  • Rest of Asia Pacific
    • By Therapy Type:
  • Chemotherapy
  • Docetaxel
  • Irinotecan
  • Trifluridine and Tipiracil
  • Carboplatin and Paclitaxel
  • Cisplatin and 5-fluorouracil
  • Cisplatin with Capecitabine
  • Targeted Drug Therapy
  • Trastuzumab
  • Ramucirumab
  • Immunotherapy
  • Pembrolizumab
    • By Disease Indication:
  • Adenocarcinomas
  • Gastrointestinal Stromal Tumors
  • Carcinoid Tumors
  • Squamous Cell Carcinoma
  • Others
    • By Distribution Channel:
  • Hospital Pharmacy
  • Retail Pharmacy
  • Online Pharmacy
  • Latin America
    • By Country:
  • Brazil
  • Mexico
  • Argentina
  • Rest of Latin America
    • By Therapy Type:
  • Chemotherapy
  • Docetaxel
  • Irinotecan
  • Trifluridine and Tipiracil
  • Carboplatin and Paclitaxel
  • Cisplatin and 5-fluorouracil
  • Cisplatin with Capecitabine
  • Targeted Drug Therapy
  • Trastuzumab
  • Ramucirumab
  • Immunotherapy
  • Pembrolizumab
    • By Disease Indication:
  • Adenocarcinomas
  • Gastrointestinal Stromal Tumors
  • Carcinoid Tumors
  • Squamous Cell Carcinoma
  • Others
    • By Distribution Channel:
  • Hospital Pharmacy
  • Retail Pharmacy
  • Online Pharmacy
  • Middle East
    • By Country:
  • GCC
  • Israel
  • Rest of Middle East
    • By Therapy Type:
  • Chemotherapy
  • Docetaxel
  • Irinotecan
  • Trifluridine and Tipiracil
  • Carboplatin and Paclitaxel
  • Cisplatin and 5-fluorouracil
  • Cisplatin with Capecitabine
  • Targeted Drug Therapy
  • Trastuzumab
  • Ramucirumab
  • Immunotherapy
  • Pembrolizumab
    • By Disease Indication:
  • Adenocarcinomas
  • Gastrointestinal Stromal Tumors
  • Carcinoid Tumors
  • Squamous Cell Carcinoma
  • Others
    • By Distribution Channel:
  • Hospital Pharmacy
  • Retail Pharmacy
  • Online Pharmacy
  • Africa
    • By Country/Region:
  • South Africa
  • Central Africa
  • North Africa
    • By Therapy Type:
  • Chemotherapy
  • Docetaxel
  • Irinotecan
  • Trifluridine and Tipiracil
  • Carboplatin and Paclitaxel
  • Cisplatin and 5-fluorouracil
  • Cisplatin with Capecitabine
  • Targeted Drug Therapy
  • Trastuzumab
  • Ramucirumab
  • Immunotherapy
  • Pembrolizumab
    • By Disease Indication:
  • Adenocarcinomas
  • Gastrointestinal Stromal Tumors
  • Carcinoid Tumors
  • Squamous Cell Carcinoma
  • Others
    • By Distribution Channel:
  • Hospital Pharmacy
  • Retail Pharmacy
  • Online Pharmacy
  • Company Profiles
  • Amgen Inc.*
    • Company Overview
    • Product Portfolio
    • Financial Performance
    • Recent Highlights
    • Strategies
  • Eli Lilly and Company
  • F. Hoffmann-La Roche
  • Bristol-Myers Squibb Company
  • Boehringer Ingelheim GmbH
  • Bristol-Myers Squibb
  • GlaxoSmithKline Plc.
  • Novartis AG
  • Johnson & Johnson
  • Gilead Sciences
  • Genentech Inc.
  • Sanofi-Aventis
  • Merck & Co.

"*" marked represents similar segmentation in other categories in the respective section.

Table of Contents

1. Research Objectives and Assumptions

  • Research Objectives
  • Assumptions
  • Abbreviations

2. Market Overview

  • Report Description
    • Market Definition and Scope
  • Executive Summary
    • Market Snippet, By Therapy Type
    • Market Snippet, By Disease Indication
    • Market Snippet, By Distribution Channel
    • Market Snippet, By Region
  • Coherent Opportunity Map (COM)

3. Market Dynamics, Regulations, and Trends Analysis

  • Market Dynamics
    • Drivers
    • Restraints
    • Market Opportunities
  • Impact Analysis
  • Market Trends
  • Key Developments
  • Regulatory Landscape
  • Product Recall
  • Epidemiology Analysis
  • Technology Overview
  • PEST Analysis
  • Porter's Five Forces model

4. Global Esophageal Cancer Drugs Market, By Therapy Type, 2017 - 2028, (US$ Million)

  • Introduction
    • Market Share Analysis, 2022 and 2028(%)
    • Y-o-Y Growth Analysis, 2017 - 2028
    • Segment Trends
  • Chemotherapy
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Million)
    • Docetaxel
    • Irinotecan
    • Trifluridine and tipiracil
    • Carboplatin and paclitaxel
    • Cisplatin and 5-fluorouracil
    • Cisplatin with capecitabine
  • Targeted Drug Therapy
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Million)
    • Trastuzumab
    • Ramucirumab
  • Immunotherapy
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Million)
    • Pembrolizumab

5. Global Esophageal Cancer Drugs Market, By Disease Indication, 2017 - 2028, (US$ Million)

  • Introduction
    • Market Share Analysis, 2022 and 2028(%)
    • Y-o-Y Growth Analysis, 2017 - 2028
    • Segment Trends
  • Adenocarcinomas
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Million)
  • Gastrointestinal Stromal Tumors
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Million)
  • Carcinoid Tumors
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Million)
  • Squamous Cell Carcinoma
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Million)
  • Others
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Million)

6. Global Esophageal Cancer Drugs Market, By Distribution Channel 2017 - 2028, (US$ Million)

  • Introduction
    • Market Share Analysis, 2022 and 2028(%)
    • Y-o-Y Growth Analysis, 2017 - 2028
    • Segment Trends
  • Hospital Pharmacy
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Million)
  • Retail Pharmacy
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Million)
  • Online Pharmacy
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Million)

7. Global Esophageal Cancer Drugs Market, By Region, 2017 - 2028, (US$ Million)

  • Introduction
    • Market Share Analysis, By Region, 2022 and 2028(%)
    • Y-o-Y Growth Analysis, By Region, 2017 - 2028
    • Regional Trends
  • North America
    • Market Size and Forecast, By Therapy Type, 2017 - 2028, (US$ Million)
    • Market Size and Forecast, By Disease Indication, 2017 - 2028, (US$ Million)
    • Market Size and Forecast, By Distribution Channel, 2017 - 2028, (US$ Million)
    • Market Size and Forecast, By Country, 2017 - 2028, (US$ Million)
    • U.S.
    • Canada
  • Europe
    • Market Size and Forecast, By Therapy Type, 2017 - 2028, (US$ Million)
    • Market Size and Forecast, By Disease Indication, 2017 - 2028, (US$ Million)
    • Market Size and Forecast, By Distribution Channel, 2017 - 2028, (US$ Million)
    • Market Size and Forecast, By Country, 2017 - 2028, (US$ Million)
    • U.K.
    • Germany
    • Italy
    • France
    • Spain
    • Russia
    • Rest of Europe
  • Asia Pacific
    • Market Size and Forecast, By Therapy Type, 2017 - 2028, (US$ Million)
    • Market Size and Forecast, By Disease Indication, 2017 - 2028, (US$ Million)
    • Market Size and Forecast, By Distribution Channel, 2017 - 2028, (US$ Million)
    • Market Size and Forecast, By Country, 2017 - 2028, (US$ Million)
    • China
    • Japan
    • India
    • ASEAN
    • Australia
    • South Korea
    • Rest of Asia Pacific
  • Latin America
    • Market Size and Forecast, By Therapy Type, 2017 - 2028, (US$ Million)
    • Market Size and Forecast, By Disease Indication, 2017 - 2028, (US$ Million)
    • Market Size and Forecast, By Distribution Channel, 2017 - 2028, (US$ Million)
    • Market Size and Forecast, By Country, 2017 - 2028, (US$ Million)
    • Brazil
    • Mexico
    • Argentina
    • Rest of Latin America
  • Africa
    • Market Size and Forecast, By Therapy Type, 2017 - 2028, (US$ Million)
    • Market Size and Forecast, By Disease Indication, 2017 - 2028, (US$ Million)
    • Market Size and Forecast, By Distribution Channel, 2017 - 2028, (US$ Million)
    • Market Size and Forecast, By Country/Region, 2017 - 2028, (US$ Million)
    • North Africa
    • Central Africa
    • South Africa
  • Middle East
    • Market Size and Forecast, By Therapy Type, 2017 - 2028, (US$ Million)
    • Market Size and Forecast, By Disease Indication, 2017 - 2028, (US$ Million)
    • Market Size and Forecast, By Distribution Channel, 2017 - 2028, (US$ Million)
    • Market Size and Forecast, By Country, 2017 - 2028, (US$ Million)
    • GCC Countries
    • Israel
    • Rest of Middle East

8. Competitive Landscape

  • Company Profiles
    • Amgen Inc.
    • Company Overview
    • Product Portfolio
    • Financial Performance
    • Recent Highlights
    • Strategies
    • Eli Lilly and Company
    • Company Overview
    • Product Portfolio
    • Financial Performance
    • Recent Highlights
    • Strategies
    • F. Hoffmann-La Roche
    • Company Overview
    • Product Portfolio
    • Financial Performance
    • Recent Highlights
    • Strategies
    • Bristol-Myers Squibb Company
    • Company Overview
    • Product Portfolio
    • Financial Performance
    • Recent Highlights
    • Strategies
    • Boehringer Ingelheim GmbH
    • Company Overview
    • Product Portfolio
    • Financial Performance
    • Recent Highlights
    • Strategies
    • Bristol-Myers Squibb
    • Company Overview
    • Product Portfolio
    • Financial Performance
    • Recent Highlights
    • Strategies
    • GlaxoSmithKline Plc.
    • Company Overview
    • Product Portfolio
    • Financial Performance
    • Recent Highlights
    • Strategies
    • Novartis AG
    • Company Overview
    • Product Portfolio
    • Financial Performance
    • Recent Highlights
    • Strategies
    • Johnson & Johnson
    • Company Overview
    • Product Portfolio
    • Financial Performance
    • Recent Highlights
    • Strategies
    • Gilead Sciences
    • Company Overview
    • Product Portfolio
    • Financial Performance
    • Recent Highlights
    • Strategies
    • Genentech Inc.
    • Company Overview
    • Product Portfolio
    • Financial Performance
    • Recent Highlights
    • Strategies
    • Sanofi-Aventis
    • Company Overview
    • Product Portfolio
    • Financial Performance
    • Recent Highlights
    • Strategies
    • Merck & Co.
    • Company Overview
    • Product Portfolio
    • Financial Performance
    • Recent Highlights
    • Strategies
  • Analyst Views

9. Section

  • References
  • Research Methodology
  • About us and Sales Contact